Partial  ||| S:0 E:8 ||| JJ
correction  ||| S:8 E:19 ||| NN
of  ||| S:19 E:22 ||| IN
the  ||| S:22 E:26 ||| DT
CNS  ||| S:26 E:30 ||| NNP
lysosomal  ||| S:30 E:40 ||| JJ
storage  ||| S:40 E:48 ||| NN
defect  ||| S:48 E:55 ||| NN
in  ||| S:55 E:58 ||| IN
a  ||| S:58 E:60 ||| DT
mouse  ||| S:60 E:66 ||| NN
model  ||| S:66 E:72 ||| NN
of  ||| S:72 E:75 ||| IN
juvenile  ||| S:75 E:84 ||| JJ
neuronal  ||| S:84 E:93 ||| JJ
ceroid  ||| S:93 E:100 ||| JJ
lipofuscinosis  ||| S:100 E:115 ||| NN
by  ||| S:115 E:118 ||| IN
neonatal  ||| S:118 E:127 ||| JJ
CNS  ||| S:127 E:131 ||| NNP
administration  ||| S:131 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
an  ||| S:149 E:152 ||| DT
adeno-associated  ||| S:152 E:169 ||| JJ
virus  ||| S:169 E:175 ||| NN
serotype  ||| S:175 E:184 ||| VBD
rh.10  ||| S:184 E:190 ||| CD
vector  ||| S:190 E:197 ||| NN
expressing  ||| S:197 E:208 ||| VBG
the  ||| S:208 E:212 ||| DT
human  ||| S:212 E:218 ||| JJ
CLN3  ||| S:218 E:223 ||| FW
gene  ||| S:223 E:228 ||| FW
Juvenile  ||| S:228 E:237 ||| FW
neuronal  ||| S:237 E:246 ||| FW
ceroid  ||| S:246 E:253 ||| FW
lipofuscinosis  ||| S:253 E:268 ||| FW
( ||| S:268 E:269 ||| -LRB-
JNCL  ||| S:269 E:274 ||| NNP
or  ||| S:274 E:277 ||| CC
CLN3  ||| S:277 E:282 ||| CD
disease ||| S:282 E:289 ||| NN
)  ||| S:289 E:291 ||| -RRB-
is  ||| S:291 E:294 ||| VBZ
an  ||| S:294 E:297 ||| DT
autosomal  ||| S:297 E:307 ||| JJ
recessive  ||| S:307 E:317 ||| JJ
lysosomal  ||| S:317 E:327 ||| JJ
storage  ||| S:327 E:335 ||| NN
disease  ||| S:335 E:343 ||| NN
resulting  ||| S:343 E:353 ||| VBG
from  ||| S:353 E:358 ||| IN
mutations  ||| S:358 E:368 ||| NNS
in  ||| S:368 E:371 ||| IN
the  ||| S:371 E:375 ||| DT
CLN3  ||| S:375 E:380 ||| JJ
gene  ||| S:380 E:385 ||| NN
that  ||| S:385 E:390 ||| IN
encodes  ||| S:390 E:398 ||| VBG
a  ||| S:398 E:400 ||| DT
lysosomal  ||| S:400 E:410 ||| JJ
membrane  ||| S:410 E:419 ||| JJ
protein ||| S:419 E:426 ||| NN
.  ||| S:426 E:428 ||| .
The  ||| S:428 E:432 ||| DT
disease  ||| S:432 E:440 ||| NN
primarily  ||| S:440 E:450 ||| RB
affects  ||| S:450 E:458 ||| VBZ
the  ||| S:458 E:462 ||| DT
brain  ||| S:462 E:468 ||| NN
with  ||| S:468 E:473 ||| IN
widespread  ||| S:473 E:484 ||| JJ
intralysosomal  ||| S:484 E:499 ||| JJ
accumulation  ||| S:499 E:512 ||| NN
of  ||| S:512 E:515 ||| IN
autofluorescent  ||| S:515 E:531 ||| JJ
material  ||| S:531 E:540 ||| NN
and  ||| S:540 E:544 ||| CC
fibrillary  ||| S:544 E:555 ||| JJ
gliosis ||| S:555 E:562 ||| NN
,  ||| S:562 E:564 ||| ,
as  ||| S:564 E:567 ||| RB
well  ||| S:567 E:572 ||| RB
as  ||| S:572 E:575 ||| IN
the  ||| S:575 E:579 ||| DT
loss  ||| S:579 E:584 ||| NN
of  ||| S:584 E:587 ||| IN
specific  ||| S:587 E:596 ||| JJ
neuronal  ||| S:596 E:605 ||| JJ
populations ||| S:605 E:616 ||| NNS
.  ||| S:616 E:618 ||| .
As  ||| S:618 E:621 ||| IN
an  ||| S:621 E:624 ||| DT
experimental  ||| S:624 E:637 ||| JJ
treatment  ||| S:637 E:647 ||| NN
for  ||| S:647 E:651 ||| IN
the  ||| S:651 E:655 ||| DT
CNS  ||| S:655 E:659 ||| NNP
manifestations  ||| S:659 E:674 ||| NNS
of  ||| S:674 E:677 ||| IN
JNCL ||| S:677 E:681 ||| NNP
,  ||| S:681 E:683 ||| ,
we  ||| S:683 E:686 ||| PRP
have  ||| S:686 E:691 ||| VBP
developed  ||| S:691 E:701 ||| VBN
a  ||| S:701 E:703 ||| DT
serotype  ||| S:703 E:712 ||| JJ
rh.10  ||| S:712 E:718 ||| CD
adeno-associated  ||| S:718 E:735 ||| JJ
virus  ||| S:735 E:741 ||| NN
vector  ||| S:741 E:748 ||| NN
expressing  ||| S:748 E:759 ||| VBG
the  ||| S:759 E:763 ||| DT
human  ||| S:763 E:769 ||| JJ
CLN3  ||| S:769 E:774 ||| NNP
cDNA  ||| S:774 E:779 ||| NNP
( ||| S:779 E:780 ||| -LRB-
AAVrh.10hCLN3 ||| S:780 E:793 ||| NNP
) ||| S:793 E:794 ||| -RRB-
.  ||| S:794 E:796 ||| .
We  ||| S:796 E:799 ||| PRP
hypothesized  ||| S:799 E:812 ||| VBD
that  ||| S:812 E:817 ||| DT
administration  ||| S:817 E:832 ||| NN
of  ||| S:832 E:835 ||| IN
AAVrh.10hCLN3  ||| S:835 E:849 ||| CD
to  ||| S:849 E:852 ||| TO
the  ||| S:852 E:856 ||| DT
Cln3 ||| S:856 E:860 ||| NNP
( ||| S:860 E:861 ||| -LRB-
Δex7 ||| S:861 E:865 ||| CD
/ ||| S:865 E:866 ||| CD
8 ||| S:866 E:867 ||| CD
)  ||| S:867 E:869 ||| -RRB-
knock-in  ||| S:869 E:878 ||| JJ
mouse  ||| S:878 E:884 ||| NN
model  ||| S:884 E:890 ||| NN
of  ||| S:890 E:893 ||| IN
JNCL  ||| S:893 E:898 ||| NNP
would  ||| S:898 E:904 ||| MD
reverse  ||| S:904 E:912 ||| VB
the  ||| S:912 E:916 ||| DT
lysosomal  ||| S:916 E:926 ||| JJ
storage  ||| S:926 E:934 ||| NN
defect ||| S:934 E:940 ||| NN
,  ||| S:940 E:942 ||| ,
as  ||| S:942 E:945 ||| RB
well  ||| S:945 E:950 ||| RB
as  ||| S:950 E:953 ||| RB
have  ||| S:953 E:958 ||| VB
a  ||| S:958 E:960 ||| DT
therapeutic  ||| S:960 E:972 ||| JJ
effect  ||| S:972 E:979 ||| NN
on  ||| S:979 E:982 ||| IN
gliosis  ||| S:982 E:990 ||| NN
and  ||| S:990 E:994 ||| CC
neuron  ||| S:994 E:1001 ||| JJ
loss ||| S:1001 E:1005 ||| NN
.  ||| S:1005 E:1007 ||| .
Newborn  ||| S:1007 E:1015 ||| NNP
Cln3 ||| S:1015 E:1019 ||| NNP
( ||| S:1019 E:1020 ||| -LRB-
Δex7 ||| S:1020 E:1024 ||| CD
/ ||| S:1024 E:1025 ||| CD
8 ||| S:1025 E:1026 ||| CD
)  ||| S:1026 E:1028 ||| -RRB-
mice  ||| S:1028 E:1033 ||| NNS
were  ||| S:1033 E:1038 ||| VBD
administered  ||| S:1038 E:1051 ||| VBN
3  ||| S:1051 E:1053 ||| CD
×  ||| S:1053 E:1055 ||| CD
10 ||| S:1055 E:1057 ||| CD
( ||| S:1057 E:1058 ||| -LRB-
10 ||| S:1058 E:1060 ||| CD
)  ||| S:1060 E:1062 ||| -RRB-
genome  ||| S:1062 E:1069 ||| JJ
copies  ||| S:1069 E:1076 ||| NNS
of  ||| S:1076 E:1079 ||| IN
AAVrh.10hCLN3  ||| S:1079 E:1093 ||| CD
to  ||| S:1093 E:1096 ||| TO
the  ||| S:1096 E:1100 ||| DT
brain ||| S:1100 E:1105 ||| NN
,  ||| S:1105 E:1107 ||| ,
with  ||| S:1107 E:1112 ||| IN
control  ||| S:1112 E:1120 ||| NN
groups  ||| S:1120 E:1127 ||| NNS
including  ||| S:1127 E:1137 ||| VBG
untreated  ||| S:1137 E:1147 ||| JJ
Cln3 ||| S:1147 E:1151 ||| NNP
( ||| S:1151 E:1152 ||| -LRB-
Δex7 ||| S:1152 E:1156 ||| CD
/ ||| S:1156 E:1157 ||| CD
8 ||| S:1157 E:1158 ||| CD
)  ||| S:1158 E:1160 ||| -RRB-
mice  ||| S:1160 E:1165 ||| NNS
and  ||| S:1165 E:1169 ||| CC
wild-type  ||| S:1169 E:1179 ||| JJ
littermate  ||| S:1179 E:1190 ||| JJ
mice ||| S:1190 E:1194 ||| NNS
.  ||| S:1194 E:1196 ||| .
After  ||| S:1196 E:1202 ||| IN
18  ||| S:1202 E:1205 ||| CD
months ||| S:1205 E:1211 ||| NNS
,  ||| S:1211 E:1213 ||| ,
CLN3  ||| S:1213 E:1218 ||| CD
transgene  ||| S:1218 E:1228 ||| JJ
expression  ||| S:1228 E:1239 ||| NN
was  ||| S:1239 E:1243 ||| VBD
detected  ||| S:1243 E:1252 ||| VBN
in  ||| S:1252 E:1255 ||| IN
various  ||| S:1255 E:1263 ||| JJ
locations  ||| S:1263 E:1273 ||| NNS
throughout  ||| S:1273 E:1284 ||| IN
the  ||| S:1284 E:1288 ||| DT
brain ||| S:1288 E:1293 ||| NN
,  ||| S:1293 E:1295 ||| ,
particularly  ||| S:1295 E:1308 ||| RB
in  ||| S:1308 E:1311 ||| IN
the  ||| S:1311 E:1315 ||| DT
hippocampus  ||| S:1315 E:1327 ||| NN
and  ||| S:1327 E:1331 ||| CC
deep  ||| S:1331 E:1336 ||| JJ
anterior  ||| S:1336 E:1345 ||| JJ
cortical  ||| S:1345 E:1354 ||| JJ
regions ||| S:1354 E:1361 ||| NNS
.  ||| S:1361 E:1363 ||| .
Changes  ||| S:1363 E:1371 ||| NNS
in  ||| S:1371 E:1374 ||| IN
the  ||| S:1374 E:1378 ||| DT
CNS  ||| S:1378 E:1382 ||| NNP
neuronal  ||| S:1382 E:1391 ||| VBD
lysosomal  ||| S:1391 E:1401 ||| JJ
accumulation  ||| S:1401 E:1414 ||| NN
of  ||| S:1414 E:1417 ||| IN
storage  ||| S:1417 E:1425 ||| NN
material  ||| S:1425 E:1434 ||| NN
were  ||| S:1434 E:1439 ||| VBD
assessed  ||| S:1439 E:1448 ||| VBN
by  ||| S:1448 E:1451 ||| IN
immunodetection  ||| S:1451 E:1467 ||| NN
of  ||| S:1467 E:1470 ||| IN
subunit  ||| S:1470 E:1478 ||| JJ
C  ||| S:1478 E:1480 ||| NNP
of  ||| S:1480 E:1483 ||| IN
ATP  ||| S:1483 E:1487 ||| NNP
synthase ||| S:1487 E:1495 ||| NN
,  ||| S:1495 E:1497 ||| ,
luxol  ||| S:1497 E:1503 ||| VBD
fast  ||| S:1503 E:1508 ||| RB
blue  ||| S:1508 E:1513 ||| JJ
staining ||| S:1513 E:1521 ||| NN
,  ||| S:1521 E:1523 ||| ,
and  ||| S:1523 E:1527 ||| CC
periodic  ||| S:1527 E:1536 ||| JJ
acid-Schiff  ||| S:1536 E:1548 ||| JJ
staining ||| S:1548 E:1556 ||| NN
.  ||| S:1556 E:1558 ||| .
For  ||| S:1558 E:1562 ||| IN
all  ||| S:1562 E:1566 ||| DT
parameters ||| S:1566 E:1576 ||| NN
,  ||| S:1576 E:1578 ||| ,
Cln3 ||| S:1578 E:1582 ||| NNP
( ||| S:1582 E:1583 ||| -LRB-
Δex7 ||| S:1583 E:1587 ||| CD
/ ||| S:1587 E:1588 ||| CD
8 ||| S:1588 E:1589 ||| CD
)  ||| S:1589 E:1591 ||| -RRB-
mice  ||| S:1591 E:1596 ||| FW
exhibited  ||| S:1596 E:1606 ||| FW
abnormal  ||| S:1606 E:1615 ||| FW
lysosomal  ||| S:1615 E:1625 ||| FW
accumulation ||| S:1625 E:1637 ||| FW
,  ||| S:1637 E:1639 ||| ,
but  ||| S:1639 E:1643 ||| CC
AAVrh.10hCLN3  ||| S:1643 E:1657 ||| CD
administration  ||| S:1657 E:1672 ||| NN
resulted  ||| S:1672 E:1681 ||| VBD
in  ||| S:1681 E:1684 ||| IN
significant  ||| S:1684 E:1696 ||| JJ
reductions  ||| S:1696 E:1707 ||| NNS
in  ||| S:1707 E:1710 ||| IN
storage  ||| S:1710 E:1718 ||| NN
material  ||| S:1718 E:1727 ||| NN
burden ||| S:1727 E:1733 ||| NN
.  ||| S:1733 E:1735 ||| .
There  ||| S:1735 E:1741 ||| EX
was  ||| S:1741 E:1745 ||| VBD
also  ||| S:1745 E:1750 ||| RB
a  ||| S:1750 E:1752 ||| DT
significant  ||| S:1752 E:1764 ||| JJ
decrease  ||| S:1764 E:1773 ||| NN
in  ||| S:1773 E:1776 ||| IN
gliosis  ||| S:1776 E:1784 ||| NN
in  ||| S:1784 E:1787 ||| IN
AAVrh.10hCLN3-treated  ||| S:1787 E:1809 ||| NNP
Cln3 ||| S:1809 E:1813 ||| NNP
( ||| S:1813 E:1814 ||| -LRB-
Δex7 ||| S:1814 E:1818 ||| CD
/ ||| S:1818 E:1819 ||| CD
8 ||| S:1819 E:1820 ||| CD
)  ||| S:1820 E:1822 ||| -RRB-
mice ||| S:1822 E:1826 ||| NNS
,  ||| S:1826 E:1828 ||| ,
and  ||| S:1828 E:1832 ||| CC
a  ||| S:1832 E:1834 ||| DT
trend  ||| S:1834 E:1840 ||| NN
toward  ||| S:1840 E:1847 ||| IN
improved  ||| S:1847 E:1856 ||| JJ
neuron  ||| S:1856 E:1863 ||| JJ
counts ||| S:1863 E:1869 ||| NNS
,  ||| S:1869 E:1871 ||| ,
compared  ||| S:1871 E:1880 ||| VBN
with  ||| S:1880 E:1885 ||| IN
their  ||| S:1885 E:1891 ||| PRP$
untreated  ||| S:1891 E:1901 ||| JJ
counterparts ||| S:1901 E:1913 ||| NNS
.  ||| S:1913 E:1915 ||| .
These  ||| S:1915 E:1921 ||| DT
data  ||| S:1921 E:1926 ||| NNS
demonstrate  ||| S:1926 E:1938 ||| VBP
that  ||| S:1938 E:1943 ||| IN
AAVrh.10  ||| S:1943 E:1952 ||| CD
delivery  ||| S:1952 E:1961 ||| NN
of  ||| S:1961 E:1964 ||| IN
a  ||| S:1964 E:1966 ||| DT
wild-type  ||| S:1966 E:1976 ||| JJ
cDNA  ||| S:1976 E:1981 ||| JJ
to  ||| S:1981 E:1984 ||| TO
the  ||| S:1984 E:1988 ||| DT
CNS  ||| S:1988 E:1992 ||| NNP
is  ||| S:1992 E:1995 ||| VBZ
not  ||| S:1995 E:1999 ||| RB
harmful  ||| S:1999 E:2007 ||| JJ
and  ||| S:2007 E:2011 ||| CC
instead  ||| S:2011 E:2019 ||| RB
provides  ||| S:2019 E:2028 ||| VBZ
a  ||| S:2028 E:2030 ||| DT
partial  ||| S:2030 E:2038 ||| JJ
correction  ||| S:2038 E:2049 ||| NN
of  ||| S:2049 E:2052 ||| IN
the  ||| S:2052 E:2056 ||| DT
neurological  ||| S:2056 E:2069 ||| JJ
lysosomal  ||| S:2069 E:2079 ||| JJ
storage  ||| S:2079 E:2087 ||| NN
defect  ||| S:2087 E:2094 ||| NN
of  ||| S:2094 E:2097 ||| IN
a  ||| S:2097 E:2099 ||| DT
disease  ||| S:2099 E:2107 ||| NN
caused  ||| S:2107 E:2114 ||| VBN
by  ||| S:2114 E:2117 ||| IN
a  ||| S:2117 E:2119 ||| DT
lysosomal  ||| S:2119 E:2129 ||| JJ
membrane  ||| S:2129 E:2138 ||| JJ
protein ||| S:2138 E:2145 ||| NN
,  ||| S:2145 E:2147 ||| ,
indicating  ||| S:2147 E:2158 ||| VBG
that  ||| S:2158 E:2163 ||| IN
this  ||| S:2163 E:2168 ||| DT
may  ||| S:2168 E:2172 ||| MD
be  ||| S:2172 E:2175 ||| VB
an  ||| S:2175 E:2178 ||| DT
effective  ||| S:2178 E:2188 ||| JJ
therapeutic  ||| S:2188 E:2200 ||| JJ
strategy  ||| S:2200 E:2209 ||| NN
for  ||| S:2209 E:2213 ||| IN
JNCL  ||| S:2213 E:2218 ||| NNP
and  ||| S:2218 E:2222 ||| CC
other  ||| S:2222 E:2228 ||| JJ
diseases  ||| S:2228 E:2237 ||| NNS
in  ||| S:2237 E:2240 ||| IN
this  ||| S:2240 E:2245 ||| DT
category ||| S:2245 E:2253 ||| NN
.  ||| S:2253 E:2255 ||| .
